Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

Biopharmaceutics and Pharmacokinetics: Overview

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026

Same author

Observations of trash in the deep tropical Atlantic and Caribbean Sea.

Marine pollution bulletin·2024

Same author

Improving outcomes and managing costs in idiopathic pulmonary fibrosis.

The American journal of managed care·2019

Same author

Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep.

Managed care (Langhorne, Pa.)·2018

Same author

New Test for Diagnosing Insulin Resistance Could Turn the Tide Against Diabetes.

Managed care (Langhorne, Pa.)·2018

Same author

Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients.

Managed care (Langhorne, Pa.)·2018

Same journal

Big pharma moves into biologics.

Biotechnology healthcare·2013

Same journal

Study: High Copayments Cut Biodrug Use up to 21 Percent.

Biotechnology healthcare·2013

Same journal

Avian flu and the quest for immunity: not just chicken feed.

Biotechnology healthcare·2013

Same journal

Variety of Biotech Therapies, Uses Take Prominence Among ASCO Presentations.

Biotechnology healthcare·2013

Same journal

Opening the door to follow-on proteins?

Biotechnology healthcare·2013

Same journal

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnology healthcare·2013

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Five steps to managing biologics.

Biotechnology Healthcare

|February 2, 2013

Summary

This summary is machine-generated.

Genomic medicine is advancing, but health plans need strategies to integrate these new treatments into benefit plans. A proposed framework can help insurers manage this complex integration process.

More Related Videos

A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood

A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood

Published on: February 8, 2016

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Related Experiment Videos

Last Updated: May 14, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood

A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood

Published on: February 8, 2016

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Area of Science:

Genomic Medicine
Health Insurance Policy

Background:

Advancements in human genome knowledge are translating into novel therapeutic products.
Health plans and insurance providers face challenges in incorporating these genomic treatments into existing medical and pharmacy benefit structures.

Purpose of the Study:

To provide a framework for health plans and insurers to address the complexities of integrating genomic medicine into benefit plans.

Main Methods:

The study proposes a strategic framework for health plan and insurer decision-making.
This framework aims to guide the incorporation of novel genomic therapies.

Main Results:

A structured approach is necessary for effective integration of genomic treatments.
The framework assists in navigating the financial and clinical considerations.

Conclusions:

Integrating genomic medicine into health benefit plans requires a systematic approach.
The proposed framework offers a practical solution for insurers to manage this evolving landscape.